CJE could inhibit gluconeogenesis and promote glycogen synthesis through the insulin-mediated IRS1-PI3K-Akt-FoxO1/GSK 3β pathway and increase glucose transport through the AMPK-GLUT4 pathway, thereby regulating glucose and lipid metabolism disorders in T2DM mice. This evidence concerns the gene FOXO1 and type 2 diabetes mellitus.